BENTZON M W, EVANS D G, MAALOE O, PERKINS F T, SPAUN J
Bull World Health Organ. 1962;26(3):341-55.
As a first step towards the standardization of poliomyelitis vaccine, the neutralizing antibody titres of ten test antipoliomyelitis sera were measured in nine laboratories in different countries in comparison with a reference preparation. A standard neutralization test was not used by all laboratories and in general those neutralizing the serum-virus mixtures at a temperature of 37 degrees C obtained higher titres than those laboratories using lower temperatures. When the potencies of the test sera were calculated, in terms of the reference preparation, there was good agreement by all laboratories with sera of similar neutralizing capacity. The reference sera used in this study have proved useful for obtaining relative potencies for poliomyelitis sera of different neutralizing capacity and of different origin. These potencies have been shown to vary much less from one laboratory to another than did the uncorrected titres.For technical reasons, these reference preparations are not considered ideal for international standard preparations, and new sera have been prepared for this purpose.
作为脊髓灰质炎疫苗标准化的第一步，在不同国家的九个实验室中，将十种试验性抗脊髓灰质炎血清的中和抗体效价与一种参考制剂进行比较测定。并非所有实验室都使用标准中和试验，一般来说，在37摄氏度温度下中和血清-病毒混合物的实验室所获得的效价比使用较低温度的实验室更高。当根据参考制剂计算试验血清的效价时，所有实验室对具有相似中和能力的血清的结果吻合度良好。本研究中使用的参考血清已证明有助于获得不同中和能力和不同来源的脊髓灰质炎血清的相对效价。已表明，这些效价在不同实验室之间的差异比未校正的效价小得多。由于技术原因，这些参考制剂不被认为是国际标准制剂的理想选择，因此已为此目的制备了新的血清。
